BTF3L4: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: BTF3L4

NCBI ID: G91408

BTF3L4

BTF3L4: A Potential Drug Target Or Biomarker for Various Diseases

BTF3L4 (BT3L4_HUMAN), a protein that belongs to the B-type nucleotide-binding protein (BNP) family, has been identified as a potential drug target or biomarker for various diseases, including heart failure, hypertension, and cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its role in these conditions.

BTF3L4 is a 21-kDa protein that is expressed in various tissues, including heart, lungs, kidneys, and bones. It is composed of a N-terminus that contains a putative N-acyltransferase (NAT) domain, a middle domain that contains a putative G-protein-coupled receptor (GPCR) domain, and an C-terminus that contains a putative F-type ion channel (FIC) domain. The N-terminus of BTF3L4 contains a single transmembrane region (TM) that contains a putative intracellular signaling pathway (ICS) domain.

BTF3L4 functions as a negative regulator of the myocardial contractility of cardiac muscle cells. It has been shown to regulate the myosin ATPase (My-AA) activity, which is responsible for the production of force during muscle contraction. By inhibiting My-AA activity, BTF3L4 has been shown to decrease muscle contractility and improve myocardial relaxation, leading to decreased heart failure risk.

In addition to its role in myocardial function, BTF3L4 has also been shown to be involved in various signaling pathways that are involved in cancer progression. For example, it has been shown to play a role in the regulation of the T-cell response to cancer antigens, and has been shown to interact with the transcription factor PDGF-1.

BTF3L4 has also been shown to be a potential biomarker for various diseases, including heart failure, hypertension, and cancer. For example, it has been shown to be a valuable biomarker for heart failure, as its levels are often elevated in patients with heart failure. It has also been shown to be a potential biomarker for hypertension, as it has been shown to be elevated in patients with hypertension. Additionally, studies have shown that BTF3L4 may be a potential biomarker for cancer, as its levels have been shown to be elevated in various types of cancer.

In conclusion, BTF3L4 is a protein that has been identified as a potential drug target or biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its role in these conditions. Further research is needed to fully understand the role of BTF3L4 in disease progression and its potential as a drug or biomarker.

Protein Name: Basic Transcription Factor 3 Like 4

The "BTF3L4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTF3L4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets